Suppr超能文献

D螺旋和H螺旋的碱性残基在肝素与蛋白C抑制剂结合中的作用。

Contribution of basic residues of the D and H helices in heparin binding to protein C inhibitor.

作者信息

Neese L L, Wolfe C A, Church F C

机构信息

Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, School of Medicine, Chapel Hill, North Carolina, 27599, USA.

出版信息

Arch Biochem Biophys. 1998 Jul 1;355(1):101-8. doi: 10.1006/abbi.1998.0716.

Abstract

Protein C inhibitor (PCI) is a heparin-binding serine protease inhibitor (serpin) that regulates hemostatic proteases such as activated protein C (APC) and thrombin. The work described here provides further evidence that the PCI H helix, but not the D helix, has a major role in heparin-accelerated inhibition of APC and thrombin. We previously identified Arg-269 and Lys-270 of the H helix [R269A/K270A "H1" recombinant PCI (rPCI)] as important residues both for heparin-accelerated inhibition of thrombin and APC and for heparin-Sepharose binding (Shirk, R. A., Elisen, M. G. L. M., Meijers, J. C. M., and Church, F. C. (1994) J. Biol. Chem. 269, 28690-28695). H1 rPCI was used as a template for Ala-scanning mutagenesis of other H helix basic residues (H1-K266A, H1-K273A, and H1-K266A/K273A) and of the D helix basic residues (H1-K82A, H1-K86A, H1-R90A, and H1-K82A/K86A/R90A). Compared to wild-type rPCI/heparin (k2 = 2.2 x 10(7) M-1 min-1 for thrombin), heparin-accelerated thrombin inhibition was decreased 2.4-fold by H1 rPCI, 4.4-fold by H1-K266A rPCI, and 8-fold by H1-K273A rPCI. H1-K266A/K273A rPCI thrombin inhibition was essentially not accelerated by heparin. A similar trend was found for APC-heparin inhibition using these H helix rPCI mutants. In contrast, the D helix rPCI mutants did not have further reduced heparin-stimulated thrombin or APC inhibition compared to H1 rPCI. Interestingly, all of the H and D helix rPCI mutants had reduced heparin-Sepharose binding activity (ranging from 180 to 360 mM NaCl) compared to wild-type rPCI and H1 rPCI, which eluted at 650 and 430 mM NaCl, respectively. These data suggest that all four basic residues (Lys-266, Arg-269, Lys-270, Lys-273) in the H helix of PCI form a heparin binding site. Our results also imply that while the D helix basic residues (Lys-80, Lys-86, and Arg-90) contribute to overall heparin binding, they are not necessary for heparin-accelerated activity. We conclude that the primary heparin binding site of PCI is the H helix and not the D helix as found in other homologous heparin-binding serpins such as antithrombin III, heparin cofactor II, and protease nexin 1.

摘要

蛋白C抑制剂(PCI)是一种肝素结合丝氨酸蛋白酶抑制剂(丝氨酸蛋白酶抑制剂),可调节诸如活化蛋白C(APC)和凝血酶等止血蛋白酶。本文所述的研究提供了进一步的证据,表明PCI的H螺旋而非D螺旋在肝素加速对APC和凝血酶的抑制中起主要作用。我们之前已确定H螺旋的精氨酸-269和赖氨酸-270 [R269A/K270A “H1” 重组PCI(rPCI)] 对于肝素加速对凝血酶和APC的抑制以及对肝素-琼脂糖结合而言都是重要残基(Shirk, R. A., Elisen, M. G. L. M., Meijers, J. C. M., and Church, F. C. (1994) J. Biol. Chem. 269, 28690 - 28695)。H1 rPCI被用作模板,对其他H螺旋碱性残基(H1-K266A、H1-K273A和H1-K266A/K273A)以及D螺旋碱性残基(H1-K82A、H1-K86A、H1-R90A和H1-K82A/K86A/R90A)进行丙氨酸扫描诱变。与野生型rPCI/肝素相比(凝血酶的k2 = 2.2×10⁷ M⁻¹ min⁻¹),H1 rPCI使肝素加速的凝血酶抑制降低了2.4倍,H1-K266A rPCI使其降低了4.4倍,H1-K273A rPCI使其降低了8倍。H1-K266A/K273A rPCI对凝血酶的抑制基本上未被肝素加速。使用这些H螺旋rPCI突变体对APC-肝素抑制也发现了类似趋势。相比之下,与H1 rPCI相比,D螺旋rPCI突变体并未使肝素刺激的凝血酶或APC抑制进一步降低。有趣的是,与分别在650和430 mM NaCl洗脱的野生型rPCI和H1 rPCI相比,所有H和D螺旋rPCI突变体的肝素-琼脂糖结合活性均降低(范围为180至360 mM NaCl)。这些数据表明,PCI的H螺旋中的所有四个碱性残基(赖氨酸-266、精氨酸-269、赖氨酸-270、赖氨酸-273)形成一个肝素结合位点。我们的结果还暗示,虽然D螺旋碱性残基(赖氨酸-80、赖氨酸-86和精氨酸-90)有助于整体肝素结合,但它们对于肝素加速活性并非必需。我们得出结论,PCI的主要肝素结合位点是H螺旋,而非其他同源肝素结合丝氨酸蛋白酶抑制剂如抗凝血酶III、肝素辅因子II和蛋白酶连接蛋白1中发现的D螺旋。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验